In summary, the biotech industry has struggled in recent years, with public markets and IPO funding dropping dramatically. In response, venture capitalists have continued to pour money into innovative platforms, providing a much-needed lifeline to fuel biotech innovation. However, many biotechs have also initiated layoffs and streamlined their project pipelines to safeguard their available cash runway.